A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy: Erratum
doi: 10.1097/FPC.0000000000000078
The authors notify readers of the following errors in Table 2 of this article 1 . These errors do not affect the conclusions of the article.
Table 2: Summary of association results of GWAS and replication study
Table 2 appears below with the corrected values shown in bold.
Reference
1. Kiyotani K, Uno S, Mushiroda T, Takahashi A, Kubo M, Mitsuhata N, et al.. A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenet Genomics 2012; 22:229–235.
Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved. View full article text